List view / Grid view
19 March 2015 | By Victoria White
UCB welcomes the Chancellor’s recognition in 2015 Budget of the relationship between scientific success and the future prosperity of the UK economy...
27 February 2015 | By UCB
"UCB continues its growth path with Cimzia®, Vimpat® and Neupro®, now accounting for 50% of our net sales. We continue to advance and prepare the launches of our next wave of potential new patient solutions: brivaracetam, epratuzumab and romosozumab..."
24 February 2015 | By UCB
UCB announced that the company’s newly appointed Chief Executive Officer, Jean-Christophe Tellier, has been selected to join the Ministerial Industry Strategy Group...
11 March 2014 | By Sanofi
Sanofi and UCB announce they have entered into a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules...
30 January 2014 | By Biogen Idec
Relationship leverages UCB’s expertise and presence in Asia to bring Biogen Idec’s Innovative therapies to patients in new markets...
1 January 2014 | By Amgen
"The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment..."
16 May 2013 | By UCB
UCB and IBM have announced the completion of the initial phase of a pioneering project...
In this Informatics In-Depth Focus: Developing Informatics for the pharmaceutical industry; Rolling out a biology ELN at UCB Pharma; Ask the Informatics experts; Laboratory Informatics – Out of the fog and into the cloud?
4 April 2012 | By Amgen
The start of sclerostin antibody Phase 3 clinical trial program announced...
5 July 2011 | By Amgen
Amgen and UCB announced that they are collaborating with the NASA Ames Research Center to conduct a preclinical test...
28 February 2011 | By UCB
UCB announced today that it has concluded an innovative research collaboration agreement with Harvard University...
